Wedbush cuts Synageva BioPharma to Neutral in valuation call

Wedbush cuts Synageva BioPharma (GEVA) to Neutral from Outperform.

"We can no longer recommend purchase of GEVA shares at current levels," analyst David Nierengarten says, noting that the stock trades at an EV/2017 sales ratio of 9, well above peers.

Price target is $67.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs